Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A ...
Xilio Therapeutics, Inc. (NASDAQ: XLO) is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, dedicated to advancing cancer treatments through innovative immuno-oncology. Founded in 2016, the company leverages a proprietary tumor-activated masking platform to design therapies that remain inactive in healthy tissues but become active in the tumor microenvironment, thereby ...Xilio Therapeutics, Inc. (NASDAQ: XLO) is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, dedicated to advancing cancer treatments through innovative immuno-oncology. Founded in 2016, the company leverages a proprietary tumor-activated masking platform to design therapies that remain inactive in healthy tissues but become active in the tumor microenvironment, thereby potentially enhancing anti-tumor immunity while minimizing systemic side effects. The company's pipeline includes XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody undergoing Phase 1/2 clinical trials for multiple solid tumors, and cytokine-based candidates such as XTX202 (engineered IL-2), XTX301 (IL-12), and XTX401 (IL-15), all designed with the same masking approach. Financially, Xilio operates as a clinical-stage firm with no commercial revenue, reflected in a market cap of about $60 million and negative profitability metrics. The company's enterprise value is negative due to a strong cash position relative to debt, and it holds a current ratio of 3.59, indicating solid short-term liquidity. R&D expenses are substantial, representing over 126% of revenue (though revenue is minimal), and the company has a net loss per share of -0.19 TTM. Key financial ratios such as return on equity (-117%) and net profit margin (-58.5%) highlight the pre-revenue stage. Xilio employs around 76 full-time employees and was led by CEO René Russo, Pharm.D., who brings extensive experience in drug development. The company went public in October 2021 and continues to focus on advancing its pipeline through clinical milestones. With a robust cash runway and a focus on tumor-selective therapies, Xilio aims to address significant unmet needs in cancer immunotherapy.
YoYYoY means Year-over-Year. It compares the latest annual value with the previous annual value to show long-term trend strength.
QoQQoQ means Quarter-over-Quarter. It compares the latest quarter with the immediately previous quarter to show short-term momentum changes.
RevenueThe total money that came through the front door from selling things, before paying a single bill. Think of it as the grand total of every credit card swipe from customers. (YoY compares this year to last year's performance, while QoQ compares the current three months to the previous three).
$43.8M
+589.9%
+47.8%
Net IncomeThe absolute bottom line. If the company paid every single supplier, employee, banker, and tax collector, this is the actual money left in their pocket at the end of the day.
$-35.0M
+39.8%
+33.1%
Gross MarginThe basic markup. If they sell a $100 pair of sneakers, this percentage tells you how much of that price tag is profit right after paying for the rubber and shoelaces, but before paying for things like store rent or TV commercials.
+96.5%
-3.5%
+2.8%
Operating MarginThe 'day job' efficiency score. Out of every dollar a customer spends, this shows how many cents the company keeps after making the product AND paying for all the everyday corporate overhead (like salaries, marketing, and keeping the lights on).
-95.9%
+90.0%
+83.3%
Net MarginThe final take-home percentage. When you strip away every conceivable cost, tax, and interest payment, this is the exact number of cents the company truly gets to keep from every dollar in sales.
-80.1%
+91.3%
+54.7%
Free Cash FlowThe holy grail of corporate cash. It's the spendable, physical money left over after the business pays for its daily operations AND buys the big, expensive upgrades (like new factories or servers) it needs to survive. This is the 'free' money they can use to pay dividends or buy back stock.
$-5.5M
+70.1%
+18.0%
FCF MarginThe ultimate cash conversion rate. It shows how good the company is at turning regular sales directly into cold, hard, spendable cash. A high percentage means the business is an absolute cash-printing machine.
-12.6%
+95.7%
+44.5%
Debt / EquityThe financial risk gauge. It compares how much of the company's empire was built using borrowed money (loans) versus the owners' own money (shareholders). A high number means they are heavily leveraged and playing a riskier game; a low number means they are playing it safe.
19.7%
-57.4%
-4.7%
Current RatioThe 12-month survival check. It simply compares the cash they have right now (plus things they can quickly turn into cash) against the immediate bills they absolutely must pay this year. A score above 1 means they have enough in the wallet to cover the upcoming bills without panicking.
2.58x
+16.6%
+18.5%
Total AssetsThe absolute size of the company's empire. It bundles together absolutely everything of value they own—from the cash in the register and the inventory in the warehouse, to the software patents in the vault and the factories on the ground.
